Testing has demonstrated Betadine's strong in-vitro virucidal activity, killing 99.99% of the SARS-CoV-2 virus in 30 seconds. The products subjected to testing were: Betadine antiseptic products, namely Solution (10% PVP-I), Skin Cleanser (7.5% PVP-I), Gargle and Mouthwash (1.0% PVP-I) and Throat Spray (0.45% PVP-I).
The research has been published in the respected Infectious Disease and Therapy Journal on 08 July 2020.
The study conducted at Duke-NUS is complemented by Laboratory testing completed at the Tropical Infectious Diseases Research and Education Center (TIDREC) at the University of Malaya, Malaysia, that also demonstrated strong in-vitro virucidal activity, with the tested product Betadine Gargle and Mouthwash (1.0% PVP-I) killing 99.99% of the SARS-CoV-2 virus in 15 seconds.
The TIDREC research has been accepted by the British Dental Journal and was published as a Letter on 26 June 2020. The journal is published by Springer Nature on behalf of the British Dental Association.
Previously, Betadine antiseptic products containing povidone iodine (PVP-I) have been proven effective in vitro against a wide range of viruses, including coronaviruses that have caused major outbreaks such as Middle East Respiratory Syndrome and Severe Acute Respiratory Syndrome.
The Betadine antiseptic range contains Povidone-iodine (PVP-I), which is highly effective against a wide range of microorganisms, including bacteria, viruses and fungi and is typically used in hospitals.
Mundipharma's independent associated companies are privately owned entities covering the world's pharmaceutical markets.
Mundipharma offers novel treatment options in fields such as pain, oncology, oncology supportive care, ophthalmology, respiratory disease and consumer healthcare.
The Betadine range of products have been trusted by hospitals and consumers around the world for over 60 years to prevent and treat infections.
Relay Therapeutics wins FDA breakthrough status for zovegalisib in breast cancer treatment
DATROWAY receives US priority review for first-line metastatic triple negative breast cancer
Valneva and Instituto Butantan launch pilot chikungunya vaccination campaign in Brazil
Lupin launches Dasatinib tablets in US market
WuXi Biologics enters into licence and research service agreement with Vertex Pharmaceuticals
Natera submits Signatera CDx PMA to FDA for bladder cancer use
Pharming receives FDA complete response letter for paediatric Joenja application
Astrazeneca Imfinzi perioperative regimen gains positive EU CHMP opinion in early gastric cancer
I Peace generates human iPS cells from NKT cells and offers them for research use
Trace Biosciences' IND application for nerve-specific imaging agent approved by FDA
Frontage expands early phase clinical research capabilities across US and China
AstraZeneca agrees obesity and type 2 diabetes collaboration with CSPC
Ascletis Pharma Inc reports topline results from Phase III open-label study of denifanstat
Innovative Molecules GmbH completes Phase 1 clinical development programme for adibelivir
MicuRx Pharmaceuticals' IND application for MRX-5 cleared by FDA